Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology, said: "The one-off oral administration of the active agent brought about a great improvement in symptoms. There were no further attacks of the disease. This could slow down the course of the disease in general.” Gruber and his team conducted the tests in cooperation with international partners from Australia, Germany and Sweden.
MS is a chronic inflammatory autoimmune disease of the central nervous system, in which the insulating myelin sheaths around the nerve fibers are destroyed. The disease progresses in the form of attacks or episodes and is currently incurable. It is estimated that around 2.5 million people are affected by MS worldwide, around 8,000 of these in Austria.
The discovery made by the Viennese scientists now offers realistic hope that the disease can be halted at a very early stage or, at the very least, its progression greatly retarded.